Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - angioedemas, nasljedni - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

Europska Unija - hrvatski - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - miglustat - gaucherova bolest - ostali prehrambeni proizvodi i proizvodi metabolizma - miglustat dipharma indiciran za oralnu liječenje odraslih bolesnika s blagom do umjereno tip 1 bolesti Гоше . miglustat dipharma može se koristiti samo u liječenju pacijenata za koje hormonske enzim terapija ne odgovara. miglustat dipharma indiciran za liječenje napreduje neuroloških poremećaja kod odraslih pacijenata i pedijatrijska bolesnika s bolesti Ниманна-vrhunac tip s .

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - molimo pogledajte dokument s informacijama o proizvodu.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - insulin human - Инсулины i kolege za injekcije, middleware akcije - cats; dogs - za liječenje dijabetesa u mačaka i pasa za smanjenje hiperglikemija i poboljšanje pridruženih kliničkih znakova.

Europska Unija - hrvatski - EMA (European Medicines Agency)

acorda therapeutics ireland limited - l-dopa - parkinsonova bolest - antiparkinsonski lijekovi - inbrija drugačije prekidima tijekom liječenja epizodne vibracija motora (video) kod odraslih pacijenata s parkinsonovom bolešću (pb) tretman s леводопы/dopa su-декарбоксилазы inhibitor.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Europska Unija - hrvatski - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - cjepiva - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Europska Unija - hrvatski - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - cjepiva - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Europska Unija - hrvatski - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabry-ovu bolest - drugi gastrointestinalni trakt i metabolizam, lijekovi, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).

Europska Unija - hrvatski - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infekcije respiratornih sincicijskih virusa - cjepiva - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.